BioStem Technologies Inc is a regenerative biotechnology company focused on harnessing elements of perinatal tissue and the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases. The company develops, manufactures, and sells tissue allografts for the wound care market with a focus on the treatment of diabetic, pressure, and venous ulcers. Utilizing its proprietary BioRetain processing method, it manufactures perinatal tissue allografts. The company offers a comprehensive portfolio of high-quality brands that are trademarked and include VENDAJE AC, AmnioWrap2, and Others. The company generates key revenue from VENDAJE AC.
Last trade$0.9262
Day change-$0.0339 (-3.53%)
Day range$0.918 – $1.02
Volume216,119
Market cap$18M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
No ratio data was found for BSEM.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
No quarterly
income statement data was found for BSEM.
Recent news
Company coverage with links to the original publishers.
BioStem Technologies reported a Q3 loss of $0.53 per share, missing EPS expectations by 23.26%, though it beat revenue estimates with $7.64 million. The company has underperformed the market significantly, down 61.4% year-to-date. With a Zacks Rank #3 (Hold) rating and mixed estimate revisions, the stock is expected to perform in line with the market.
BioStem Technologies announced that its VENDAJE and VENDAJE AC placental-derived wound care products have been added to existing contracts with Vizient and Premier, the two largest Group Purchasing Organizations in the U.S. This marks the first GPO contract coverage for these products and is expected to significantly expand hospital access and support the company's commercial strategy.
BioStem Technologies Inc. (OTC: BSEM), a regenerative medicine company specializing in perinatal tissue allograft products, announced that Nasdaq has approved its common stock for listing on The Nasdaq Capital Market. Trading under ticker symbol 'BSEM' is expected to begin on August 7, 2026. The uplisting is expected to expand the company's access to capital, improve market visibility and liquidity, and enhance its ability to attract talent.
BioStem Technologies (OTC: BSEM), a MedTech company specializing in perinatal tissue-derived products for advanced wound care, announced that company management will present at the 46th Annual TD Cowen Healthcare Conference on March 2, 2026, in Boston. The presentation will be accessible via live and archived webcasts on the company's investor relations website.
BioStem Technologies (OTC:BSEM) announced the closing of its acquisition of BioTissue Holdings' surgical and wound care business for approximately $15 million upfront, with potential milestone payments up to $25 million. The acquisition includes the Neox® and Clarix® product lines, a nationwide sales force, and GPO contracts. The acquired assets generated $29 million in 2025 sales and are expected to contribute positive EBITDA in 2026. Barry Hassett was promoted to Chief Commercial Officer to lead the combined commercial team.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.